Alembic Pharmaceuticals on Friday said its joint venture (JV) firm Aleor Dermaceuticals has received approval from the US health regulator for Clobetasol Propionate spray, used to treat plaque psoriasis.
The approved product is therapeutically equivalent to the reference listed drug product (RLD), Clobex spray, 0.05 per cent of Galderma Laboratories L P.
"Aleor Dermaceuticals Ltd has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Clobetasol Propionate Spray, 0.05 per cent," Alembic Pharmaceuticals said in a regulatory filing.
Clobetasol Propionate Spray, 0.05 per cent is indicated for the treatment of moderate to severe plaque psoriasis.
Quoting IQVIA data, Alembic Pharma said Clobetasol Propionate Spray, 0.05 per cent, has an estimated market size of USD 22 million for twelve months ending December 2018.
Alembic has a cumulative total of 103 ANDA approvals (91 final approvals and 12 tentative approvals) from USFDA.
Shares of Alembic Pharma were trading 1.80 per cent higher at Rs 535 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app